KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 123 filers reported holding KEROS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $527,645 | +17.9% | 16,551 | +48.5% | 0.00% | – |
| Q2 2023 | $447,685 | +0.4% | 11,142 | +6.7% | 0.00% | – |
| Q1 2023 | $445,874 | +18.6% | 10,442 | +33.4% | 0.00% | – |
| Q4 2022 | $375,853 | +24.0% | 7,827 | -2.8% | 0.00% | – |
| Q3 2022 | $303,000 | -20.1% | 8,056 | +15.4% | 0.00% | – |
| Q1 2022 | $379,000 | -6.7% | 6,980 | +0.6% | 0.00% | – |
| Q4 2021 | $406,000 | +34.9% | 6,937 | -9.0% | 0.00% | – |
| Q3 2021 | $301,000 | -90.6% | 7,627 | -89.9% | 0.00% | -100.0% |
| Q2 2021 | $3,206,000 | -72.8% | 75,504 | -60.6% | 0.00% | -66.7% |
| Q1 2021 | $11,783,000 | -12.0% | 191,423 | +0.9% | 0.00% | -25.0% |
| Q4 2020 | $13,383,000 | +84.5% | 189,719 | +0.9% | 0.00% | +100.0% |
| Q3 2020 | $7,254,000 | -35.9% | 188,082 | -37.7% | 0.00% | -50.0% |
| Q2 2020 | $11,322,000 | – | 301,825 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 321,300 | $12,087,000 | 4.99% |
| First Light Asset Management, LLC | 598,213 | $22,505,000 | 2.28% |
| Nantahala Capital Management | 845,692 | $31,815,000 | 2.06% |
| CHI Advisors LLC | 200,229 | $7,533,000 | 2.03% |
| Fairmount Funds Management LLC | 272,498 | $10,251,000 | 1.80% |
| Altium Capital Management LP | 88,000 | $3,311,000 | 1.21% |
| Orbimed Advisors | 1,679,417 | $63,180,000 | 1.17% |
| SPHERA FUNDS MANAGEMENT LTD. | 206,819 | $7,781,000 | 1.08% |
| Parkman Healthcare Partners LLC | 99,927 | $3,759,000 | 1.07% |
| Soleus Capital Management, L.P. | 146,000 | $5,493,000 | 0.75% |